Literature DB >> 29417467

Pulmonary Vascular Disease: Hemodynamic Assessment and Treatment Selection-Focus on Group II Pulmonary Hypertension.

Bhavadharini Ramu1, Brian A Houston1, Ryan J Tedford2.   

Abstract

PURPOSE OF REVIEW: Pulmonary hypertension due to left heart disease (PH-LHD) is the most common cause of pulmonary hypertension worldwide, yet therapies used to treat pulmonary arterial hypertension have failed to show efficacy in this population. Proper hemodynamic assessment and differentiation of pulmonary hypertension phenotypes is therefore critical for both current clinical practice and future research and therapeutic efforts. RECENT
FINDINGS: Substantial recent efforts have sought to improve the hemodynamic characterization of pulmonary hypertension for both diagnostic and prognostic purposes. These efforts include identifying occult LHD using provocative maneuvers as well as sub-classifying PH-LHD based on the presence or absence of a pre-capillary component. How to best define the pre-capillary component remains controversial as several studies have drawn conflicting conclusions. The lack of standardization of hemodynamic measurements as well as measurement fidelity concerns may explain some of the discrepant results. Non-hemodynamic methods of PH-LHD classification may also have an emerging role. Despite recent advances, therapeutic studies have largely remained disappointing. In this review, we discuss the nuances and controversies surrounding diagnostic and prognostic hemodynamic characterization of PH-LHD as well as summarize the recent therapeutic efforts and ongoing challenges in this population.

Entities:  

Keywords:  Hemodynamics; Left heart disease; Pulmonary hypertension; Right heart catheterization

Mesh:

Year:  2018        PMID: 29417467     DOI: 10.1007/s11897-018-0377-9

Source DB:  PubMed          Journal:  Curr Heart Fail Rep        ISSN: 1546-9530


  126 in total

1.  2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Mark H Drazner; Gregg C Fonarow; Stephen A Geraci; Tamara Horwich; James L Januzzi; Maryl R Johnson; Edward K Kasper; Wayne C Levy; Frederick A Masoudi; Patrick E McBride; John J V McMurray; Judith E Mitchell; Pamela N Peterson; Barbara Riegel; Flora Sam; Lynne W Stevenson; W H Wilson Tang; Emily J Tsai; Bruce L Wilkoff
Journal:  Circulation       Date:  2013-06-05       Impact factor: 29.690

2.  Unexplained exertional dyspnea caused by low ventricular filling pressures: results from clinical invasive cardiopulmonary exercise testing.

Authors:  William M Oldham; Gregory D Lewis; Alexander R Opotowsky; Aaron B Waxman; David M Systrom
Journal:  Pulm Circ       Date:  2016-03       Impact factor: 3.017

3.  How to define pulmonary hypertension due to left heart disease.

Authors:  Mario Gerges; Christian Gerges; Irene M Lang
Journal:  Eur Respir J       Date:  2016-05-12       Impact factor: 16.671

4.  Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT).

Authors:  Thomas F Lüscher; Frank Enseleit; Richard Pacher; Veselin Mitrovic; Matthias R Schulze; Roland Willenbrock; Rainer Dietz; Valentin Rousson; David Hürlimann; Sebastian Philipp; Thomas Notter; Georg Noll; Frank Ruschitzka
Journal:  Circulation       Date:  2002-11-19       Impact factor: 29.690

5.  The diastolic pulmonary gradient does not predict survival in patients with pulmonary hypertension due to left heart disease.

Authors:  Emmanouil Tampakakis; Peter J Leary; Van N Selby; Teresa De Marco; Thomas P Cappola; G Michael Felker; Stuart D Russell; Edward K Kasper; Ryan J Tedford
Journal:  JACC Heart Fail       Date:  2014-11-12       Impact factor: 12.035

6.  Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study.

Authors:  Milton Packer; John McMurray; Barry M Massie; Abraham Caspi; Vincent Charlon; Alain Cohen-Solal; Wolfgang Kiowski; William Kostuk; Henry Krum; Barry Levine; Paolo Rizzon; Jordi Soler; Karl Swedberg; Susan Anderson; David L Demets
Journal:  J Card Fail       Date:  2005-02       Impact factor: 5.712

7.  A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST).

Authors:  R M Califf; K F Adams; W J McKenna; M Gheorghiade; B F Uretsky; S E McNulty; H Darius; K Schulman; F Zannad; E Handberg-Thurmond; F E Harrell; W Wheeler; J Soler-Soler; K Swedberg
Journal:  Am Heart J       Date:  1997-07       Impact factor: 4.749

8.  Clinical Relevance of Fluid Challenge in Patients Evaluated for Pulmonary Hypertension.

Authors:  Michele D'Alto; Emanuele Romeo; Paola Argiento; Yoshiki Motoji; Anna Correra; Giovanni Maria Di Marco; Agostino Mattera Iacono; Rosaria Barracano; Antonello D'Andrea; Gaetano Rea; Berardo Sarubbi; Maria Giovanna Russo; Robert Naeije
Journal:  Chest       Date:  2016-08-26       Impact factor: 9.410

9.  Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.

Authors:  Margaret M Redfield; Horng H Chen; Barry A Borlaug; Marc J Semigran; Kerry L Lee; Gregory Lewis; Martin M LeWinter; Jean L Rouleau; David A Bull; Douglas L Mann; Anita Deswal; Lynne W Stevenson; Michael M Givertz; Elizabeth O Ofili; Christopher M O'Connor; G Michael Felker; Steven R Goldsmith; Bradley A Bart; Steven E McNulty; Jenny C Ibarra; Grace Lin; Jae K Oh; Manesh R Patel; Raymond J Kim; Russell P Tracy; Eric J Velazquez; Kevin J Anstrom; Adrian F Hernandez; Alice M Mascette; Eugene Braunwald
Journal:  JAMA       Date:  2013-03-27       Impact factor: 56.272

10.  PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support.

Authors:  Ryan J Tedford; Anna R Hemnes; Stuart D Russell; Ilan S Wittstein; Mobusher Mahmud; Ari L Zaiman; Stephen C Mathai; David R Thiemann; Paul M Hassoun; Reda E Girgis; Jonathan B Orens; Ashish S Shah; David Yuh; John V Conte; Hunter C Champion
Journal:  Circ Heart Fail       Date:  2008-11       Impact factor: 8.790

View more
  1 in total

1.  Features Associated With Discordance Between Pulmonary Arterial Wedge Pressure and Left Ventricular End Diastolic Pressure in Clinical Practice: Implications for Pulmonary Hypertension Classification.

Authors:  Anna R Hemnes; Alexander R Opotowsky; Tufik R Assad; Meng Xu; Laura N Doss; Eric Farber-Eger; Quinn S Wells; Evan L Brittain
Journal:  Chest       Date:  2018-08-24       Impact factor: 9.410

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.